Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity

Patent metadata

Field	Value
Publication number	US-9517243-B2
Application number	US-201514879476-A
Country	US
Kind code	B2
Filing date	Oct 9, 2015
Priority date	Mar 12, 2010
Publication date	Dec 13, 2016
Grant date	Dec 13, 2016

Abstract

β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.

First claim

The invention claimed is:

1. A composition comprising a β-mannosylceramide (β-ManCer) or salt or solvate thereof in a pharmaceutically acceptable carrier, wherein the β-ManCer consists of a β-mannosyl moiety linked to a ceramide moiety, the ceramide moiety consisting of:
a) a sphingosine moiety linked to
b) a fatty acid moiety comprising a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from about 8 to about 49 carbon atoms, wherein the composition further comprises a therapeutically effective amount of one or more chemotherapeutic agents.

2. The composition of claim 1 , wherein the fatty acid moiety comprises a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from about 8 to about 15 carbon atoms.

3. The composition of claim 1 , wherein the fatty acid moiety comprises a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from about 18 to about 30 carbon atoms.

4. The composition of claim 1 , wherein the composition further comprises a therapeutically effective amount of IL-2.

5. The composition of claim 1 , wherein the composition further comprises a therapeutically effective amount of an α-glycosylceramide or a salt or solvate thereof.

6. The composition of claim 1 , wherein the composition further comprises GM-CSF, and/or other cytokines that induce cellular immunity.

7. The composition claim 6 , wherein the cytokines that induce cellular immunity include IL-12 and/or IL-15.

8. The composition of claim 1 , wherein the composition further comprises one or more T-cell co-stimulatory molecules, wherein the one or more co-stimulatory molecules are selected from the group consisting of B7-1, B7-2, B7-3, B7-H, ICAM1, ICAM2, ICAM3, LFA1, LFA2, LFA3, CD40L, OX40L and 4-1BBL.

9. The composition of claim 1 , wherein the composition further comprises one or more Toll-like Receptor (TLR) ligands.

10. The composition of claim 9 , wherein the one or more TLR ligands are selected from the group consisting of ligands for TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9.

11. The composition of claim 1 , wherein the composition further comprises a vaccine.

12. The composition of claim 11 , wherein the vaccine is selected from the group consisting of TARP 29-37-9V peptide, and Sargramostin (GM-CSF) emulsified in Montanide ISA 51 VG.

13. The composition of claim 1 , wherein the composition further comprises an antibody.

14. The composition of claim 13 , wherein the antibody is selected from the group consisting of antibodies against CTLA-4 or PD-1 or TGF-beta.

15. A method of inducing an immune response, treating cancer, or inhibiting growth of a tumor in a subject, the method comprising administering to the subject the composition of claim 1 in an amount effective to induce an immune response, treat cancer, or inhibit growth of a tumor, wherein the cancer is selected from the group consisting of liver cancer, brain cancer, neck cancer, skin cancer, lung cancer, kidney cancer, stomach cancer, colon cancer, prostate cancer, breast cancer, ovarian cancer, melanoma and lymphoid cancer and the tumor is selected from the group consisting of a lung tumor, a breast tumor, a colon tumor, a liver tumor, a brain tumor, a neck tumor, a prostate tumor, an ovarian tumor, a skin tumor, a melanoma tumor and a lymphoid tumor in the subject.

16. A method of making the composition according to claim 1 , the method comprising:
reacting 2-amino-1-O-β-mannopyranosyl-D-ribo-1,3,4-octadecanetriol with an electrophile to form β-ManCer; and
combining the β-ManCer with a pharmaceutically acceptable carrier and the one or more chemotherapy agents.

Assignees

• The Us Secretary Dept Of Health And Humam Services
• The Univ Of Birmingham Of Edgbaston
• Us Health
• The Univ Of Birmingham Of Edgbaston

Inventors

• Berzofsky Jay A
• O'Konek Jessica J
• Terabe Masaki
• Illarionov Petr A
• Besra Gurdyal S

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K31/7004

  Monosaccharides having only carbon, hydrogen and oxygen atoms · CPC title

• A61K2039/585

  wherein the target is cancer · CPC title

• A61K38/2013

  IL-2 · CPC title